Review
doi: 10.3389/fneph.2024.1459425. eCollection 2024.Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia
Affiliations
- PMID:39502472
- PMCID: PMC11534831
- DOI: 10.3389/fneph.2024.1459425
Item in Clipboard
Review
Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia
Amit Joharapurkar et al. Front Nephrol..
Display options
Format
Display options
Format
Abstract
Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the preclinical and clinical profile of desidustat which led to its approval and clinical use in India.
Keywords: HIF; chronic kidney disease-induced anemia; hemoglobin; hepcidin; prolyl hydroxylase inhibitor.
Copyright © 2024 Joharapurkar, Pandya, Patel, Jain and Desai.
Conflict of interest statement
Authors AJ, VP, HP, MJ, and RD was/were employed by Zydus Lifesciences Limited.
Similar articles
- Desidustat: First Approval.Dhillon S.Dhillon S.Drugs. 2022 Jul;82(11):1207-1212. doi: 10.1007/s40265-022-01744-w.Drugs. 2022.PMID:35834123Free PMC article.Review.
- Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Jain MR.Joharapurkar AA, et al.Drug Dev Res. 2021 Sep;82(6):852-860. doi: 10.1002/ddr.21792. Epub 2021 Jan 22.Drug Dev Res. 2021.PMID:33480036
- Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Kajavadara C, Valani D, Jain MR.Joharapurkar AA, et al.Curr Res Pharmacol Drug Discov. 2022 Apr 30;3:100102. doi: 10.1016/j.crphar.2022.100102. eCollection 2022.Curr Res Pharmacol Drug Discov. 2022.PMID:35570856Free PMC article.
- HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.Patel VJ, Joharapurkar A, Kshirsagar SG, Patel MS, Savsani HH, Dodiya HS, Rakhasiya MH, Kajavadara C, Valani D, Jain MR.Patel VJ, et al.Toxicol Appl Pharmacol. 2024 Feb;483:116832. doi: 10.1016/j.taap.2024.116832. Epub 2024 Jan 22.Toxicol Appl Pharmacol. 2024.PMID:38266872
- Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR.Joharapurkar AA, et al.J Med Chem. 2018 Aug 23;61(16):6964-6982. doi: 10.1021/acs.jmedchem.7b01686. Epub 2018 May 9.J Med Chem. 2018.PMID:29712435Review.
References
- St Peter WL, Guo H, Kabadi S, Gilbertson DT, Peng Y, Pendergraft T, et al. . Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. (2018) 19:67. doi: 10.1186/s12882-018-0861-1 - DOI - PMC - PubMed
- Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, et al. . Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta- analysis in a global consortium. Am J Kidney Dis. (2019) 73:206–17. doi: 10.1053/j.ajkd.2018.08.013 - DOI - PMC - PubMed
Publication types
Related information
Grants and funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
LinkOut - more resources
Full Text Sources